|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Nadav Kidron||CEO, Pres & Exec. Director||1,03M||N/D||1974|
|Mr. Joshua Hexter||Chief Operating & Bus. Officer||238,4k||N/D||1970|
|Dr. Miriam Kidron||Chief Scientific Officer & Director||333,85k||N/D||1940|
|Mr. Avraham Gabay||CFO, Treasurer & Sec.||N/D||N/D||1985|
|Dr. Roy Eldor M.D., Ph.D.||Chief Medical Advisor & Member of the Scientific Advisory Board||N/D||N/D||N/D|
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
L'ISS Governance QualityScore di Oramed Pharmaceuticals Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.